Questing for Integrin Targeting Theranostics for Cancer Cell-Selective Molecules

Area of Science:

• Medicinal Chemistry
• Molecular Imaging
• Cancer Therapeutics

Background:

• Theranostic agents combine diagnosis and therapy for severe diseases like cancer.
• Effective theranostics require therapeutic, imaging, and targeting components for specific cell recognition.

Purpose of the Study:

• To synthesize and evaluate novel small molecules (D and E) as potential theranostic agents for cancer.
• To assess the molecules' properties including integrin binding, cellular adhesion, photophysical characteristics, and cytotoxic effects.

Main Methods:

• Synthesis of two novel theranostic molecules, D and E, incorporating a β-lactam moiety, a fluorophore, and a cytotoxic unit.
• Evaluation of photophysical properties, α4β1 integrin binding affinity, and adhesion assays using various cell lines.
• Assessment of compound E's efficacy as a photosensitizer and its cellular uptake mechanisms.

Main Results:

• Compound E demonstrated good affinity for α4β1 integrin and retained selective agonist activity in adhesion assays.
• Photosensitization of compound E induced significant, concentration-dependent cell viability reduction across tested cell lines.
• Internalization studies revealed nonselective cellular uptake of compound E, attributed to its high lipophilicity.

Conclusions:

• Compound E exhibits promising theranostic potential, with selective integrin targeting and potent photosensitized cytotoxicity.
• High lipophilicity influences compound E's cellular uptake, potentially impacting targeted delivery despite specific binding.
• Further optimization may be needed to enhance targeted delivery and therapeutic efficacy of these novel theranostic agents.